期刊文献+

二甲双胍与利拉鲁肽联合治疗2型糖尿病患者的临床效果观察 被引量:4

Observation on the clinical effect of metformin combined with liraglutide in the treatment of patients with type 2 diabetes mellitus
下载PDF
导出
摘要 目的:分析二甲双胍与利拉鲁肽联合治疗2型糖尿病患者的临床效果。方法:收治2型糖尿病患者86例,平分两组。对照组给予二甲双胍治疗,研究组在此基础上给予利拉鲁肽治疗;对比两组血糖各项指标水平、不良反应发生率。结果:与对照组相比较,研究组患者治疗之后的血糖各项指标水平明显更优,差异有统计学意义(P<0.05)。结论:二甲双胍与利拉鲁肽联合治疗2型糖尿病患者的临床效果十分显著。 Objective:To analyze the clinical effect of metformin and liraglutide combined treatment in patients with type 2diabetes mellitus.Methods:86 patients with type 2 diabetes mellitus were selected.They were randomly divided into the two groups on average.The control group was treated with metformin.The research group received liraglutide treatment on the basis of the control group.The levels of blood glucose and the incidence of adverse reactions were compared between groups.Results:Compared with the control group,the levels of blood glucose after treatment in the study group was significantly better,and the difference was statistically significant(P<0.05).Conclusion:The clinical effect of metformin and liraglutide combined therapy in the treatment of patients with type 2 diabetes is very significant.
出处 《中国社区医师》 2017年第17期55-56,共2页 Chinese Community Doctors
关键词 二甲双胍 利拉鲁肽 2型糖尿病 Metformin Liraglutide Type 2 diabetes mellitus
  • 相关文献

参考文献6

二级参考文献60

  • 1糖尿病诊疗标准(一)——美国糖尿病学会(ADA)2005年公布[J].国外医学(内分泌学分册),2005,25(6):436-437. 被引量:69
  • 2国家药典委员会.中国药典(三部)[S].北京:化学工业出版社,2010:238.
  • 3Nauck M, Stockmann F, Ebert R, et al. Reduced incre- tin effect in type 2 (non-insulin-dependent) diabetes [ J]. Diabetologia, 1986,29( 1 ) :46-52.
  • 4Martin J H, Deacon C F, Gorrell M D, et al. Incretin- based therapies-review of the physiology, pharmacology and emerging clinical experience [J]. Intern Med J, 2011,41 (4) :299-307.
  • 5Nathan D M, Schreiber E, Fogel H, et al. Insulinotropic action of glucagonlike peptide-I-(7-37 ) in diabetic and nondiabetic subjects [ J ]. Diabetes Care, 1992,15 ( 2 ) : 270 -276.
  • 6Kreymann B, Williams G, Ghatei M A, et al. Glucagon- like peptide-1 7-36: a physiological incretin in man[ J]. Lancet, 1987,2 (8571) :1300-1304.
  • 7Nauck M A, Niedereichholz U, Ettler R, et al. Gluca- gon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans [ J ]. Am J Physiol, 1997,273(5 Pt 1) :E981-E988.
  • 8Willms B, Werner J, Hoist J J, et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 ( GLP- 1) -(7-36) amide in type 2 (noninsulin-dependent) dia- betic patients [J]. J Clin Endocrinol Metab, 1996, 81 ( 1 ) :327-332.
  • 9Flint A, Raben A, Astrup A, et al. Glucagon-like pep- tide 1 promotes satiety and suppresses energy intake in humans[ J]. J Clin Invest, 1998,101 (3) :515-520.
  • 10Gutzwiller J P, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in pa- tients with diabetes mellitus type 2 [ J]. Am J Physiol, 1999,276(5 Pt 2) :R1541-R1554,.

共引文献104

同被引文献34

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部